Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — IL-15 Celiac Disease Phase 2a Topline Results - Conference Call (September 2026)
23 slides from Teva Pharmaceutical Industries's conference presentation, Sep 2, 2026
Slide 1: TEV-'408 (Anti-IL-15) Positive Celiac Disease Phase 2a Topline Results
TEV-’408 (Anti-IL-15) Positive Celiac Disease Phase 2a Topline Results September 2, 2026
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our futu
Slide 3: Introduction, TEV-'408 Data, Q&A
1 Introduction President and Chief Executive Officer 2 TEV-’408 (anti-IL-15) Data EVP, Global R&D & Chief Medical Officer 3 Q&A EVP, Chief Financial Officer 3|
Slide 4: President and Chief Executive Officer
President and Chief Executive Officer 4|
Slide 5: Key anticipated milestones for 2026
Assets Key anticipated milestone for 2026 Timing duvakitug UC/CD Phase 2 maintenance data H1’26 ecopipam NDA accepted by the FDA with priority review H1’26 Vitiligo Phase 1b topline results H1'26 Anti-IL-15 Celiac Phase 2a topline results H2'26 DARI Targeted completion of pivotal Phase 3 studies H2'
Slide 6: Late-stage pipeline assets
Late-stage pipeline assets Peak sales Estimated Ambition to grow and accelerate pipeline Targeted submission potential1 Market size2 olanzapine LAI Preparing for launch Schizophrenia LAI franchise ecopipam (EBS-101) Tourette Syndrome Preparing for launch DARI (ICS-SABA) Enrollment completed for Asth
Slide 7: Executive Vice President, Global R&D & Chief Medical Officer
Executive Vice President, Global R&D & Chief Medical Officer 7|
Slide 8: Diet Alone Does Not Address Disease Burden
No approved ~1% / 5.1M ~50% Blunted villi, IL-15-driven therapy crypt hyperplasia intraepithelial of US + EU5 adults with with persistent - lower Vh:Cd lymphocyte relies on strict lifelong (IEL) expansion celiac disease symptoms despite gluten-free diet gluten-free diet Diet Alone Does Not Address D
Slide 9: IL-15 activates IELs in celiac gut tissue
IL-15 from stressed epithelium Activated IELs kill enterocytes gluten stress ongoing attack 1. Normal gut tissue 2. IL-15 activates IELs 3. Celiac gut tissue Tall, intact villi with a healthy villous IL-15 from stressed epithelium primes Sustained IEL cytotoxicity flattens villi height : crypt depth
Slide 10: More effective IL-15 reduction in mice
Affinity TEV-’408 COMP1* COMP2* Binding affinity SPR IL-15:IL-15Ra KD (pM) 81.4 631 128 Binding affinity KinExA IL-15:IL-15Ra KD (pM) 1.86 100.80 9.63 * Generated based on published sequences More effective IL-15 reduction in mice, single administration of different doses TEV-’408 *COMP 1 *COMP 2 No
Slide 11: Enteropathy Reversed in Gluten-Sensitive Macaques
Enteropathy Reversed in Gluten-Sensitive Macaques — Step 2 of Our Translational Chain Villous height : crypt depth (Vh:Cd) Supporting findings ratio returned to normal Intraepithelial lymphocytes (IELs) normalized IEL counts in jejunal biopsies fell to normal levels Vh:Cd (p<0.001) On Gluten diet He
Slide 12: TEV-'408 Serum Levels: Evidence of IL-15 blockade
TEV-’408 Serum Levels Evidence of IL-15 blockade Following Single Dose administration in healthy volunteers Free IL-15 in healthy volunteers; well tolerated Mean Free IL15 change from Baseline (%) 120 60 0 -60 -120 0 40 80 120 Nominal Time (Days) Dose A TEV-’408 Dose B TEV-’408 Dose C TEV-’408 Place
Slide 13: Gut Protection Signal Used to De-Risk Phase 2a
Gut Protection Signal Used to De-Risk Phase 2a TEV-’408 Key takeaway Anti-IL-15 suppressed the gluten- triggered Fatty Acid Binding Protein (FABP) to below pre-treatment levels • Placebo FABP rose ~50% during the 14- week gluten challenge • TEV-’408 FABP fell to ~–30% by week 17 • Nominal p<0.05 vs
Slide 14: Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Design
Randomized, Double-Blind, Placebo-Controlled Biopsy-Endpoint Study with Safety Follow-Up Screening biopsy Single SC injection Daily gluten challenge Intestinal biopsy baseline measure Day 1 Weeks 2-8 Week 8: primary endpoint TEV-’408 SC, Day 1 R Follow-up through Week 80 Screening 1:1 Assesses durab
Slide 15: Phase 2a met primary endpoint: Vh:Cd ratio and IEL density
Phase 2a met primary endpoint: Vh:Cd ratio at Week 8 Reduced intestinal inflammation: IEL density at Week 8 LS mean change from baseline in IEL density (IELs per 100 enterocytes) 0.0 0.0 -0.1 Placebo +27.60 Treatment difference -0.2 -0.2 −27.23 LS mean change from baselines -0.3 TEV-’408 +0.373 −39.
Slide 16: Vh:Cd change from baseline across studies
Villous height : crypt depth (Vh:Cd) change from baseline across studies — Teva’s benefit from a single dose Program Antibody dose & Study & design* Vh:Cd ratio outcome Company route TEV-’408 Ph 2a Treatment difference 0.45 SC single dose Teva 6 weeks gluten challenge p<0.05 10 mg/kg IV FB102 Ph 1b
Slide 17: Phase 2a Proof of Concept Further Derisks TEV-'408
Phase 2a Proof of Concept Further Derisks TEV-’408 ~1.6M Zero ~$1.5-2B Adults with diagnosed celiac disease in the Approved pharmaceutical therapies available Peak sales potential, non-risk adjusted initial target population today Why Now No approved pharmacotherapy — a gluten-free First anti-IL-15
Slide 18: Cross-Indication Evidence Supporting Vitiligo Phase 2b
Cross-Indication Evidence Supporting Vitiligo Phase 2b in 2026; Two SC Doses 12 Weeks Apart Well Tolerated Two patients scored themselves “very much improved” Patient photos removed to protect the patient's privacy Patient photos removed to protect the patient's privacy Patient scoring using Patient
Slide 19: Safety summary across Phase 1, 1b and 2a studies
Phase 1 Phase 1b Phase 2a Phase 1b Healthy volunteers Celiac Patients Celiac Patients Vitiligo Patients Single ascending and multiple Exploratory safety and biomarker Exploratory safety and biopsy Exploratory safety and efficacy doses across five dose levels gluten challenge study gluten challenge s
Slide 20: IL-15-driven indications and patient populations
Bone marrow Skin epidermis Hair follicle Gut epithelium PATIENT INDICATIONS POPULATION* Celiac Disease 1.6M Gastroenterology Eosinophilic Esophagitis 0.6M IL-15 Vitiligo 4.1M Dermatology Alopecia Areata 2.1M Atopic Dermatitis 23.9M IL-15-driven indications; list illustrative and not exhaustive Antig
Slide 21: Combines Clinical Proof of Concept, Durable Pharmacology and Multi-Indication Potential
Combines Clinical Proof of Concept, Durable Pharmacology and Multi-Indication Potential Differentiated profile Clinical data Path & expansion • Internally developed, potential best- • Positive topline results from Phase 2a • Fast-track celiac; multiple-dose Phase in-class anti-IL-15 antibody celiac
Slide 22: Q&A
Q8A
Slide 23: We are all in for better health
v We are all in for better health